Sonoma Pharmaceuticals, Inc. (SNOA)
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.3M
- Net income
- -$3.5M
- Total assets
- $13.7M
- Market cap
- $4.0M
- Gross margin
- 38.0%
- Operating margin
- -12.6%
- Net margin
- -16.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $19.5M
- Cost of revenue
- $12.1M
- Gross profit
- $7.4M
- Operating expenses
- $9.9M
- Operating income
- -$2.5M
- Income tax
- -$244.0K
- Net income
- -$3.2M
- EPS (basic)
- $-1.89
- EPS (diluted)
- $-1.89
Balance sheet
- Total assets
- $14.0M
- Current assets
- $12.1M
- Total liabilities
- $10.9M
- Current liabilities
- $4.8M
- Shareholders’ equity
- $3.1M
Cash flow
- Operating cash flow
- -$3.9M
- Investing cash flow
- -$192.0K
- Financing cash flow
- $477.0K
- Net cash flow
- -$3.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.0M
- EPS (diluted)
- $-1.89
- Shares outstanding
- 3.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 25, 2007
Sonoma Pharmaceuticals, Inc. (SNOA) Stock Price
- Reported a net loss of $3.5M in FY2025.
- Revenue grew 55% from FY2022 to FY2026.
- Gross margin of 38.0%, net margin -16.3%.
- Trading 79% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Sonoma Pharmaceuticals, Inc..
Write a review
News about Sonoma Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Sonoma Pharmaceuticals, Inc.: frequently asked questions
Is Sonoma Pharmaceuticals, Inc. an American company?
Sonoma Pharmaceuticals, Inc. is a US-based company headquartered in Boulder, Colorado, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Sonoma Pharmaceuticals, Inc. headquartered?
Sonoma Pharmaceuticals, Inc. is headquartered in Boulder, Colorado, United States.
Is Sonoma Pharmaceuticals, Inc. publicly traded?
Yes — Sonoma Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol SNOA on the NASDAQ.
What does Sonoma Pharmaceuticals, Inc. do?
Sonoma Pharmaceuticals, Inc. is an American Medical Devices company in the Health & Beauty sector.
